EN DE
Watch ISU Abxis Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ISU Abxis Co. Ltd (086890) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of ISU Abxis Co. Ltd stock KRW 727, price KRW 3,335, that is 78.2% below the price, quality 18 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7086890001

IA ISU Abxis Co. Ltd logo Thin data Nov 8, 2026

ISU Abxis Co. Ltd

086890 · KQ
Very expensive, weak quality

Our calculation puts a fair price 78% below what the stock costs today.

Low debt
Generates free cash flow over the last twelve months
Revenue last quarter +86% vs. a year ago.
Expensive Growth (revenue 5y +17.2 %/yr in KRW)
Thin margins · 0.8% net margin (TTM)
Fair value 727.12 KRW · Strongly overvalued
Quality 18/100
Trails peers (2/9)
Narrow moat 14/100 · thin data
Thin data
⚠ Dilution
Watch ISU Abxis Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

16,500 KRW 2,975 KRW Fair Value 727.12 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 2,975 KRW – 16,500 KRW · fair‑value band 702.13 KRW – 747.24 KRW · the 3,335 KRW price screens above the 727.12 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow ISU Abxis Co. in your weekly email

Every Wednesday you see whether ISU Abxis Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide.

Show moreShow less

The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; and Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications.

It is also developing ISU104, a human antibody for the treatment of refractory cancer; ISU304, a modified recombinant factor IX protein for the treatment of Hemophilia B patients; and ISU305, an antibody biosimilar for paroxysmal nocturnal hemoglobinuria therapy.

ISU Abxis Co., Ltd. is headquartered in Seongnam, South Korea.

Stock analysis

ISU Abxis Co. Ltd (086890) currently trades at 3,335 KRW, while our model-based Fair Value estimate is 727.12 KRW, 78% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of 855.44 KRW per share, and 0 of the 6 models we run sit above the 3,335 KRW price.

Bear case: the Multiples group reads lowest at 587.64 KRW, and 6 of the 6 models stay below the price. Data coverage for this calculation is low.

Scenario range: 702.13 KRW (bear) to 747.24 KRW (bull), the price of 3,335 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 18/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

ISU Abxis Co. Ltd reported revenue of 56.7B KRW in FY2025 versus 28.0B KRW in FY2021, a compound +19.3%/yr. Reported net income was −10.7B KRW in FY2025.

Key figures

Market cap 146B KRW (≈ $108M) Micro · P/S ratio 3.67 · Net margin 0.8% · Return on equity 2,806% · Return on assets (EBIT) −3.9% (5-year average) · Operating margin −22.1% · Revenue (TTM) 39.6B KRW · Revenue growth (YoY) +86.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 14 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −14% fair-value upside, at −78%, 086890 screens richer than that median.

Fair Value models

Bear 702.13 KRW Fair Value 727.12 KRW Bull 747.24 KRW
Price 3,335 KRW · Downside -78.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 826.04 KRW 855.44 KRW 879.10 KRW 72
ROIC Compounder 826.04 KRW 855.44 KRW 879.10 KRW 71
EV/EBITDA 1,547 KRW 2,100 KRW 2,653 KRW 66
All 6 models by family
Earnings-Based
EPV 826.04 KRW 855.44 KRW 879.10 KRW 72
Multiples
EV/EBIT 412.53 KRW 587.64 KRW 762.76 KRW 64
EV/EBITDA 1,547 KRW 2,100 KRW 2,653 KRW 66
EV/Revenue 262.14 KRW 422.83 KRW 583.52 KRW 51
Asset-Based
NCAV (Graham) 432.71 KRW 655.63 KRW 819.53 KRW 53
Economic Profit
ROIC Compounder 826.04 KRW 855.44 KRW 879.10 KRW 71

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 18/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 8
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 54
Debt, balance sheet and risk of trouble
Investment 26
Does it invest with discipline instead of growing at any price?
Low Volatility 40
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 9
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 51/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
Start year 2020 (pandemic). Over 10 years: +17.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−75.3% (2019) → −12.5% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

086890 screens overvalued: fair value 78% below the price. Compare with ST Pharm Co →

Compare ISU Abxis Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 54 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 18 · Bottom 25%
Fair Value upside −78.2% · Bottom 25%
Profitability
Return on assets −6.7% · Bottom 25%
Net margin (12 months) 0.8% · Bottom 25%
Operating margin (12 months) −22.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 86.4% · Top 25%

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 1.27× · Pricier than median
P/S (12 months) 3.67× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 13
FUTURE (revenue growth)100 · sector 51
PAST (return on equity)0 · sector 15
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 26

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Kolon Life Science Inc 102940 12,450 KRW 37,195 KRW +199% vs 086890
Huons Global Co 084110 18,880 KRW 47,019 KRW +149% vs 086890
DongKook Pharmaceutical Co 086450 23,350 KRW 28,372 KRW +22% vs 086890
VIKRAMTH VIKRAMTH ₹324.45 ₹351.29 +8% vs 086890
ST Pharm Co 237690 71,500 KRW 61,182 KRW −14% vs 086890
EURO EURO 1.26 PHP 0.8000 PHP −37% vs 086890
Oscotec Inc 039200 36,150 KRW 21,262 KRW −41% vs 086890
BINEX Co 053030 6,140 KRW 1,844 KRW −70% vs 086890
Caregen Co 214370 27,500 KRW 5,414 KRW −80% vs 086890
SHUKRAPHAR SHUKRAPHAR ₹82.11 ₹9.14 −89% vs 086890

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ISU Abxis Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ISU Abxis Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/086890

Frequently asked questions

Is ISU Abxis Co. Ltd (086890) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 727.12 KRW versus a price of 3,335 KRW, about 78% lower (overvalued).
What is the fair value of 086890?
Our model-based fair value for ISU Abxis Co. Ltd is 727.12 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 3,335 KRW.
What is the quality score of 086890?
ISU Abxis Co. Ltd has a Quality Score of 18/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ISU Abxis Co. Ltd (086890)?
Our model-based price target is the fair value of 727.12 KRW (as of Nov 8, 2026) from 6 valuation models. Cautious scenario 702.13 KRW, optimistic scenario 747.24 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ISU Abxis Co. Ltd stock forecast for 2026?
Our models put fair value at 727.12 KRW, about 78% lower versus a price of 3,335 KRW (overvalued). Cautious scenario 702.13 KRW, optimistic scenario 747.24 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ISU Abxis Co. Ltd (086890)?
ISU Abxis Co. Ltd reported trailing-twelve-month revenue of about 39.6B KRW (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of ISU Abxis Co. Ltd (086890)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ISU Abxis Co. Ltd it is 727.12 KRW per share (as of Nov 8, 2026), against a price of 3,335 KRW. It is the blended result of 6 valuation models in 4 families (Earnings-Based, Multiples, Asset-Based, Economic Profit).
Is ISU Abxis Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 086890 trades above its calculated fair value: price 3,335 KRW, fair value 727.12 KRW, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 086890?
No. The price is what the market pays today (3,335 KRW); the fair value is what the company's own numbers justify (727.12 KRW). For ISU Abxis Co. Ltd the two are 2,608 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ISU Abxis Co. Ltd worth?
The market values ISU Abxis Co. Ltd at about 146B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 3,335 KRW; our models calculate a fair value of 727.12 KRW per share.
What do the bullish and bearish scenarios say about 086890?
Our models span a range for ISU Abxis Co. Ltd: cautious scenario 702.13 KRW, base 727.12 KRW, optimistic 747.24 KRW per share (as of Nov 8, 2026, price 3,335 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 086890 from its 52-week high?
ISU Abxis Co. Ltd trades at 3,335 KRW, about 47% below its 52-week high of 6,240 KRW and 12% above the low of 2,975 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 727.12 KRW is for.
Which stocks are comparable to ISU Abxis Co. Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ISU Abxis Co. Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 3,335 KRW, calculated fair value 727.12 KRW (−78%), Quality Score 18/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 086890 calculated?
We run ISU Abxis Co. Ltd through 6 models from 4 families: Earnings-Based, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of 727.12 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. ISU Abxis Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ISU Abxis Co. Ltd (086890)?
The closing price on Nov 9, 2026 was 3,335 KRW. Our model-based fair value is 727.12 KRW, about 78% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ISU Abxis Co. Ltd right now?
The price sits above even our optimistic bull case (747.24 KRW). The favourable scenario is already priced in. Weak quality (18/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (702.13 KRW to 747.24 KRW), unusually little disagreement for a valuation.

Key figures of ISU Abxis Co. Ltd

How large is the market capitalisation of ISU Abxis Co. Ltd (086890)?
The market capitalisation of ISU Abxis Co. Ltd is 146B KRW (≈ $108M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ISU Abxis Co. Ltd (086890)?
The price-to-sales ratio of ISU Abxis Co. Ltd is 3.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ISU Abxis Co. Ltd (086890)?
The net margin of ISU Abxis Co. Ltd is 0.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ISU Abxis Co. Ltd (086890)?
The return on equity (ROE) of ISU Abxis Co. Ltd is 2,806% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ISU Abxis Co. Ltd (086890)?
On an EBIT basis the return on assets of ISU Abxis Co. Ltd is −3.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ISU Abxis Co. Ltd (086890)?
The operating margin of ISU Abxis Co. Ltd is −22.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ISU Abxis Co. Ltd (086890)?
Revenue at ISU Abxis Co. Ltd is growing +86.4% versus a year earlier (3y avg +11.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ISU Abxis Co. Ltd (086890) generate?
The free cash flow of ISU Abxis Co. Ltd is −89.7M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ISU Abxis Co. Ltd (086890) carry?
The net debt of ISU Abxis Co. Ltd is 4.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ISU Abxis Co. Ltd in the live analysis

One click puts ISU Abxis Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.